99 related articles for article (PubMed ID: 16711753)
21. Evaluation of the binding between potential anti-HIV DNA-based drugs and viral envelope glycoprotein gp120 by capillary electrophoresis with laser-induced fluorescence detection.
Zhou W; Tomer KB; Khaledi MG
Anal Biochem; 2000 Sep; 284(2):334-41. PubMed ID: 10964417
[TBL] [Abstract][Full Text] [Related]
22. Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication.
Auwerx J; Isacsson O; Söderlund J; Balzarini J; Johansson M; Lundberg M
Int J Biochem Cell Biol; 2009 Jun; 41(6):1269-75. PubMed ID: 19038358
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.
Andrianov AM; Anishchenko IV; Tuzikov AV
J Chem Inf Model; 2011 Oct; 51(10):2760-7. PubMed ID: 21888425
[TBL] [Abstract][Full Text] [Related]
24. Anti-HIV-1 activity of low molecular weight sulfated chitooligosaccharides.
Artan M; Karadeniz F; Karagozlu MZ; Kim MM; Kim SK
Carbohydr Res; 2010 Mar; 345(5):656-62. PubMed ID: 20117763
[TBL] [Abstract][Full Text] [Related]
25. Comparative molecular dynamics simulations of HIV-1 integrase and the T66I/M154I mutant: binding modes and drug resistance to a diketo acid inhibitor.
Brigo A; Lee KW; Fogolari F; Mustata GI; Briggs JM
Proteins; 2005 Jun; 59(4):723-41. PubMed ID: 15815973
[TBL] [Abstract][Full Text] [Related]
26. [Conformation of the HIV-1 gp120 V3 loop. Structure functional analysis of the HIV-Haiti viral strain].
Andrianov AM
Tsitologiia; 2006; 48(11):948-57. PubMed ID: 17233480
[TBL] [Abstract][Full Text] [Related]
27. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.
Li H; Song H; Heredia A; Le N; Redfield R; Lewis GK; Wang LX
Bioconjug Chem; 2004; 15(4):783-9. PubMed ID: 15264865
[TBL] [Abstract][Full Text] [Related]
28. ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection.
Xun T; Li W; Chen J; Yu F; Xu W; Wang Q; Yu R; Li X; Zhou X; Lu L; Jiang S; Li L; Tan S; Liu S
Antimicrob Agents Chemother; 2015 Sep; 59(9):5123-34. PubMed ID: 26055369
[TBL] [Abstract][Full Text] [Related]
29. Genotypic coreceptor analysis.
Sierra S; Kaiser R; Thielen A; Lengauer T
Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
[TBL] [Abstract][Full Text] [Related]
30. Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120.
Tan H; Rader AJ
Proteins; 2009 Mar; 74(4):881-94. PubMed ID: 18704932
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of HIV-1 envelope-mediated fusion by synthetic batzelladine analogues.
Bewley CA; Ray S; Cohen F; Collins SK; Overman LE
J Nat Prod; 2004 Aug; 67(8):1319-24. PubMed ID: 15332849
[TBL] [Abstract][Full Text] [Related]
32. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
[TBL] [Abstract][Full Text] [Related]
33. Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120.
Sayer N; Ibrahim J; Turner K; Tahiri-Alaoui A; James W
Biochem Biophys Res Commun; 2002 May; 293(3):924-31. PubMed ID: 12051747
[TBL] [Abstract][Full Text] [Related]
34. Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency.
Cushman M; Insaf S; Paul G; Ruell JA; De Clercq E; Schols D; Pannecouque C; Witvrouw M; Schaeffer CA; Turpin JA; Williamson K; Rice WG
J Med Chem; 1999 May; 42(10):1767-77. PubMed ID: 10346929
[TBL] [Abstract][Full Text] [Related]
35. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Huskens D; Vermeire K; Profy AT; Schols D
Antiviral Res; 2009 Oct; 84(1):38-47. PubMed ID: 19664662
[TBL] [Abstract][Full Text] [Related]
36. In silico study on indole derivatives as anti HIV-1 agents: a combined docking, molecular dynamics and 3D-QSAR study.
Balupuri A; Gadhe CG; Balasubramanian PK; Kothandan G; Cho SJ
Arch Pharm Res; 2014 Aug; 37(8):1001-15. PubMed ID: 24338530
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound.
Tomassi C; Nguyen VN; Marco-Contelles J; Balzarini J; Pannecouque C; De Clercq E; Soriano E; Postel D
Bioorg Med Chem Lett; 2008 Apr; 18(7):2277-81. PubMed ID: 18353641
[TBL] [Abstract][Full Text] [Related]
38. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.
Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K
Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923
[TBL] [Abstract][Full Text] [Related]
39. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
Li Z; Han J; Chen HF
Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
[TBL] [Abstract][Full Text] [Related]
40. A conserved molecular action of native and recombinant Epap-1 in inhibition of HIV-1 gp120 mediated viral entry.
Roda Rani KP; Pelluru D; Kondapi AK
Arch Biochem Biophys; 2006 Dec; 456(1):79-92. PubMed ID: 17078922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
